Merck KGaA stock (DE0006599905): Latest developments and business overview

Merck KGaA maintains its position as a key player in life sciences, electronics, and healthcare solutions. The company reported steady progress in its core segments during its most recent quarterly update, with healthcare revenue holding firm despite market headwinds, according to Merck IR as of 05/13/2026. This update underscores its resilience for US investors eyeing international diversification.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Merck KGaA: core business model

Merck KGaA operates through three main pillars: Healthcare, Life Science, and Electronics. The Healthcare division focuses on innovative therapies in oncology and neurology, including blockbuster drugs like Mavenclad for multiple sclerosis. Life Science provides tools and services for biotech research and manufacturing, while Electronics specializes in liquid crystals for displays and OLED materials. This diversified model generated €22.0 billion in net sales for fiscal 2024, as reported in the annual results published March 2025, according to Merck annual report as of 03/2025.

The company's strategy emphasizes R&D investment, with €3.6 billion allocated in 2024, representing about 16% of sales. This supports a pipeline of over 20 projects in clinical development, targeting high-growth areas like immunology and fertility treatments.

Main revenue and product drivers for Merck KGaA

Healthcare contributes around 40% of revenue, driven by oncology products such as Bavencio, co-developed with Pfizer, which posted €1.2 billion in sales for 2024 per the annual filing. Life Science, the largest segment at 42%, benefits from bioprocessing demand amid global vaccine production ramps. Electronics, at 18%, leads in semiconductor and display materials, with sales growth tied to consumer electronics cycles.

Key growth drivers include strategic acquisitions like the 2023 purchase of Lectinity for €50 million to bolster glycosylation tools, and partnerships with US firms like Moderna for mRNA tech, enhancing US market exposure as noted in Merck's investor updates through Q1 2026.

Industry trends and competitive position

Merck KGaA competes with giants like Thermo Fisher in life sciences and Samsung in electronics materials. The life sciences tools market is projected to grow at 8% CAGR through 2030, per Gartner as of 2025, where Merck holds a top-5 share. In pharma, its focus on precision medicine positions it against Roche and Novartis.

Electronics benefits from AI-driven demand for advanced materials, with Merck supplying 30% of global liquid crystal volume. US investors value its role in the semiconductor supply chain, indirectly supporting Nvidia and AMD ecosystems.

Why Merck KGaA matters for US investors

Merck KGaA offers US investors access via OTC-traded MKKGY shares, providing exposure to Europe's pharma innovation without direct EU listing hassles. Its US revenue share exceeds 25%, driven by subsidiaries like MilliporeSigma, a key supplier to American biotech hubs in Boston and San Diego.

With the US biotech funding rebound in 2025-2026, Merck's tools segment stands to gain, mirroring peers' gains amid Fed rate cuts boosting valuations.

Conclusion

Merck KGaA demonstrates solid fundamentals across its diversified segments, with ongoing R&D fueling long-term potential in life sciences and electronics. While market cycles pose challenges, its global footprint and innovation pipeline offer balanced exposure. US investors monitor its US-centric growth amid evolving trade dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.